{
    "clinical_study": {
        "@rank": "40439", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs such as thalidomide may stop the growth of cancer cells by stopping blood\n      flow to the tumor.\n\n      PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating women who have\n      epithelial ovarian cancer that has not responded to previous therapy."
        }, 
        "brief_title": "Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the time to progression of disease in patients with platinum-refractory or\n           resistant ovarian epithelial carcinoma treated with thalidomide.\n\n        -  Evaluate the quality of life of patients treated with this regimen.\n\n      OUTLINE: Patients receive oral thalidomide once daily. Treatment continues in the absence of\n      disease progression or unacceptable toxicity.\n\n      Quality of life is assessed at baseline and then every 4 weeks.\n\n      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 9-15 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed ovarian epithelial carcinoma\n\n          -  Platinum-refractory or resistant disease\n\n               -  At least 1 prior non-platinum chemotherapy agent required\n\n          -  Prior bilateral salpingo-oophorectomy and hysterectomy required\n\n          -  Bidimensionally measurable disease OR CA-125 greater than 100 units/mm3\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  AST no greater than 2.5 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 50 mL/min\n\n        Other:\n\n          -  No other prior malignancy except non-melanoma skin cancer unless curatively treated\n             with no evidence of disease within the past 5 years and at low risk for recurrence\n\n          -  No other clinical circumstances that would preclude study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since prior biologic therapy and recovered\n\n          -  No prior thalidomide\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior cytotoxic therapy and recovered\n\n        Endocrine therapy:\n\n          -  At least 4 weeks since prior hormonal therapy and recovered\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior major surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00016224", 
            "org_study_id": "01-006", 
            "secondary_id": [
                "CDR0000068611", 
                "NCI-G01-1943"
            ]
        }, 
        "intervention": {
            "intervention_name": "thalidomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Thalidomide"
        }, 
        "keyword": "recurrent ovarian epithelial cancer", 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01006"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of Thalidomide in Patients With Ovarian Cancer", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "David R. Spriggs, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00016224"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}